Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2011

View Archived Issues

Promising data described from several trials of natalizumab in RRMS

Incyte and Pfizer disclose favorable preclinical data on chemokine CCR2 receptor antagonist

Phase III results show immunogenicity of quadrivalent flu vaccine in children

Actilyse approved in 15 European countries to treat acute ischemic stroke

Nitazoxanide evaluated in viral respiratory infections

Researchers at Novartis disclose new kinesin-like protein KIF11 inhibitors

Novel candidate therapeutics prepared for ophthalmic diseases

Sanofi presents novel protease-activated PAR1 receptor antagonists

New MAP kinase p38 inhibitors designed by RespiVert

NanoViricides raises funds to advance new influenza candidate

Synageva BioPharma and Trimeris complete merger

Acadia Pharmaceuticals clear to test AM-831 in clinic

Novel HIV reverse transcriptase inhibitor prodrugs disclosed

Functional Genetics completes first-in-human FGI-101-1A6 trial

FDA recognizes Velcade extends survival of patients with multiple myeloma

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Daiichi Sankyo gains Brazilian rights to drug for overactive bladder

First RENAISSANCE phase III trial does not meet primary endpoint

Pilot study evaluates apremilast in ankylosing spondylitis

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

FDA approves U.S. market return for Octagam

Artisan Pharma becomes wholly owned subsidiary of Asahi Kasei Pharma

Amgen to pay ImmunoGen milestone for use of TAP technology

Recordati's Normosang approved in Russia

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...